Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Net Cash Flow (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Net Cash Flow for 12 consecutive years, with -$9.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 98.38% to -$9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.2 million through Dec 2025, up 91.16% year-over-year, with the annual reading at $52.2 million for FY2025, 91.16% up from the prior year.
  • Net Cash Flow hit -$9.6 million in Q4 2025 for vTv Therapeutics, down from $72.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $72.6 million in Q3 2025 to a low of -$9.6 million in Q4 2025.
  • Historically, Net Cash Flow has averaged $4.2 million across 5 years, with a median of -$2.9 million in 2022.
  • Biggest five-year swings in Net Cash Flow: crashed 499.42% in 2024 and later soared 1935.2% in 2025.
  • Year by year, Net Cash Flow stood at -$6.2 million in 2021, then skyrocketed by 47.76% to -$3.2 million in 2022, then surged by 137.6% to $1.2 million in 2023, then plummeted by 499.42% to -$4.8 million in 2024, then plummeted by 98.38% to -$9.6 million in 2025.
  • Business Quant data shows Net Cash Flow for VTVT at -$9.6 million in Q4 2025, $72.6 million in Q3 2025, and -$5.1 million in Q2 2025.